Next Article in Journal
Controlled-Release from High-Loaded Reservoir-Type Systems—A Case Study of Ethylene-Vinyl Acetate and Progesterone
Previous Article in Journal
17β-Estradiol Delivered in Eye Drops: Evidence of Impact on Protein Networks and Associated Biological Processes in the Rat Retina through Quantitative Proteomics
Review

Opportunities and Challenges in the Delivery of mRNA-Based Vaccines

Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen Ø, Denmark
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(2), 102; https://doi.org/10.3390/pharmaceutics12020102
Received: 28 December 2019 / Revised: 22 January 2020 / Accepted: 26 January 2020 / Published: 28 January 2020
In the past few years, there has been increasing focus on the use of messenger RNA (mRNA) as a new therapeutic modality. Current clinical efforts encompassing mRNA-based drugs are directed toward infectious disease vaccines, cancer immunotherapies, therapeutic protein replacement therapies, and treatment of genetic diseases. However, challenges that impede the successful translation of these molecules into drugs are that (i) mRNA is a very large molecule, (ii) it is intrinsically unstable and prone to degradation by nucleases, and (iii) it activates the immune system. Although some of these challenges have been partially solved by means of chemical modification of the mRNA, intracellular delivery of mRNA still represents a major hurdle. The clinical translation of mRNA-based therapeutics requires delivery technologies that can ensure stabilization of mRNA under physiological conditions. Here, we (i) review opportunities and challenges in the delivery of mRNA-based therapeutics with a focus on non-viral delivery systems, (ii) present the clinical status of mRNA vaccines, and (iii) highlight perspectives on the future of this promising new type of medicine. View Full-Text
Keywords: mRNA; vaccines; therapeutic; prophylactic; drug delivery systems; lipids; polymers; nanoparticles; nanomedicine mRNA; vaccines; therapeutic; prophylactic; drug delivery systems; lipids; polymers; nanoparticles; nanomedicine
Show Figures

Figure 1

MDPI and ACS Style

Wadhwa, A.; Aljabbari, A.; Lokras, A.; Foged, C.; Thakur, A. Opportunities and Challenges in the Delivery of mRNA-Based Vaccines. Pharmaceutics 2020, 12, 102. https://doi.org/10.3390/pharmaceutics12020102

AMA Style

Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Opportunities and Challenges in the Delivery of mRNA-Based Vaccines. Pharmaceutics. 2020; 12(2):102. https://doi.org/10.3390/pharmaceutics12020102

Chicago/Turabian Style

Wadhwa, Abishek, Anas Aljabbari, Abhijeet Lokras, Camilla Foged, and Aneesh Thakur. 2020. "Opportunities and Challenges in the Delivery of mRNA-Based Vaccines" Pharmaceutics 12, no. 2: 102. https://doi.org/10.3390/pharmaceutics12020102

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop